Read news on lymphomas with our app.
Read more in the app
Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study
PARP1 Inhibitor Shows Promise Against EBV-Associated Lymphomas by Targeting EBNA2/MYC Pathway
Investigators develop novel treatment for T-cell leukemias and lymphomas
